Loading patent…
AssigneeNanoVation Therapeutics Inc.
InventorsMartin Attwood, Daniel Kurek, Jessica A.F.D. Silva, Jayesh Kulkarni
Estimating the term…
The present disclosure provides a method for delivery of nucleic acid to a T cell to produce a modified T cell, the method comprising contacting a lipid nanoparticle encapsulating the nucleic acid with the T cell ex vivo or in vivo, thereby causing cellular uptake of the nucleic acid, the lipid nanoparticle having between 30 mol % and 70 mol % of a neutral or zwitterionic amphipathic lipid having a net-neutral charge at physiological pH, an ionizable cationic lipid, and a sterol, wherein the lipid nanoparticle is substantially uncharged at physiological pH and has an apparent pKa of between 6.0 and 7.5, wherein the nucleic acid modifies the T cell to provide a T cell having a therapeutic, prophylactic or ameliorative effect in vivo. Further provided are compositions for use thereof and T cell preparations.
A method for delivery of nucleic acid to a T cell to produce a modified T cell, the method comprising contacting a lipid nanoparticle encapsulating the nucleic acid with the T cell ex vivo or in vivo, thereby causing cellular uptake of the nucleic acid, the lipid nanoparticle having between 30 mol % and 70 mol % of a neutral or zwitterionic amphipathic lipid having a net-neutral charge at physiological pH, an ionizable cationic lipid, and optionally a sterol, wherein the lipid nanoparticle is substantially uncharged at physiological pH and has an apparent pKa of between 6.0 and 7.5, wherein the nucleic acid modifies the T cell by:
A lipid nanoparticle comprising an encapsulated nucleic acid for ex vivo or in vivo delivery to a T cell to produce a modified T cell having a therapeutic, prophylactic or ameliorative effect in vivo, the lipid nanoparticle having between 30 mol % and 70 mol % of neutral lipid or zwitterionic amphipathic lipid having a neutral or net-neutral charge at physiological pH, an ionizable cationic lipid, and optionally a sterol, wherein the lipid nanoparticle is substantially uncharged at physiological pH and has an apparent pKa of between 6.0 and 7.5, wherein the nucleic acid is for modifying the T cell by:
A lipid nanoparticle comprising an encapsulated nucleic acid for ex vivo or in vivo delivery to a T cell to produce a modified T cell having a therapeutic, prophylactic or ameliorative effect in vivo, the lipid nanoparticle having between 30 mol % and 70 mol % of neutral lipid or zwitterionic amphipathic lipid having a neutral or net-neutral charge at physiological pH, an ionizable cationic lipid, and optionally a sterol, wherein the lipid nanoparticle is substantially uncharged at physiological pH and has an apparent pKa of between 6.0 and 7.5, wherein the nucleic acid is for modifying the T cell and wherein the lipid nanoparticle has less than 1.5 mol % PEG-lipid.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.